Key Press Releases

Q-Sera’s innovative blood clotting technology granted patent in US

August 19, 2019

Medical device company Q-Sera Pty Ltd today announces that it has received a Notice of Allowance from the United States Patent & Trademark Office for the foundation patent of its innovative blood clotting technology for use in blood collection tubes.

The Q-Sera technology is based on lead active RAPClotTM which has been shown to rapidly produce high quality serum for biochemical analysis, even if the blood sample contains anti-coagulants. The ability to clot all blood samples in less than five minutes, including those containing anti-coagulants which affect around 10 percent of hospital patients, make the technology a game changer.

In acute situations where speed matters such as emergency departments, blood tests are commonly used to assist the accurate diagnosis of medical problems ranging from heart attacks to diabetes. A delay in test results means a delay in diagnosis and the right care for very sick patients. Having access to a technology that universally clots all blood samples within 5 minutes will contribute to improved patient outcomes and reduced healthcare costs.

“Q-Sera is delighted with this tremendous milestone, as it underlines the value of our technology as a ‘universal’ blood collection tube to produce high-quality serum. The issued patent provides protection through 2030 in the United States, which is a key market for us,” says Q-Sera CEO Michael Grant.

Q-Sera’s technology now has patent protection for use in blood collection tubes in the United States, Europe, Japan, China, Mexico, Russia, Canada, South Africa and Australia. Q-Sera is progressing additional patents to cover novel formulations and expanded uses for its unique actives, extending the commercial opportunities.

International Expert in Blood Collection Tubes joins Q-Sera

October 2, 2018

Q-Sera Pty Ltd (Q-Sera) is pleased to announce the addition of international consultant and expert in the field of blood collection tubes, Franz E. Kirchmeir to our growing company to further R&D efforts and assist in the commercialization of the RAPClot™ technology.

Franz was previously the Director of Business Development at Greiner Bio-One Preanalytics at their global headquarters in Austria. He brings 20 years’ experience in the pre-analytical business sector including blood collection tubes, as well as extensive knowledge in R&D management, business development and strategic management. Q-Sera is pleased to welcome Franz to the team to help bring our technology into international markets.

Read more

Q-Sera’s innovative blood clotting technology patent granted in China

November 27, 2017

Q-Sera Pty Ltd (Q-Sera) is pleased to announce that the foundation patent for its innovative blood clotting technology, RAPClot™, has been granted in China which joins a growing list of countries where the patent has now been granted which include the EU, Japan and Australia.

Read more

Q-Sera’s innovative blood clotting technology presented at leading international scientific conference

October 23, 2017

A poster presentation on Q-Sera’s recombinant prothrombin activator RAPClot™ technology for blood collection tubes was made at the 23rd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC Worldlab) in Durban, South Africa.

Read more

Publications

Zhao et al, Next-generation rapid serum tube technology using prothrombin activator coagulant: fast, high quality serum from normal samples. Clin Chem Lab Med 2019 Mar 26; 57(4):483-497.
 
Studies showing blood clotting action of venom prothrombin activator OsPA derived from Australian Coastal Taipan in blood collection tubes. These results demonstrate rapid generation of high-quality serum, contributing to faster turnaround times with standardised quality samples, for accurate analyte determinations in normal individuals.